FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897543997> ?p ?o ?g. }

• W2897543997 endingPage "660" @default.
• W2897543997 startingPage "647" @default.
• W2897543997 abstract ": Anti-programmed death (ligand)-1 [anti-PD-(L)1] therapies such as pembrolizumab, nivolumab or atezolizumab have become standard of care for non-small cell lung cancer (NSCLC) patients either in first line or beyond. PD-L1 expression level allows enriching the treated population with responders, but it is still not an optimal biomarker. Even in patients with PD-L1 tumor proportion score (TPS) levels of ≥50% treated with first line pembrolizumab overall response rate (ORR) is only 44.8% and overall survival at one year is 70%. Moreover, in combination trials with chemotherapy and anti-PD-(L)1 therapy, a significant proportion of patients does not respond (ORR ranges from 45.3% to 64.0%), regardless of PD-L1 expression. Furthermore, PD-L1 expression level is not associated with improved benefit in patients treated with combinations of anti-PD-(L)1 and anti-cytotoxic T-lymphocyte-associated antigen (anti-CTLA4) therapy. One of the new promising biomarkers is tumor mutational burden (TMB). It has been discovered that especially tumor types with a known high mutation rate such as NSCLC and melanoma respond best to immune checkpoint inhibitors (ICIs). An explanation is that this high mutation rate makes it more likely that neoantigens arise that are targeted by activated immune cells, but it is not feasible to determine neoantigen load in daily practice. However, TMB of a certain tumor type is associated with neoantigen load and outcome on ICIs. In this comprehensive review, we discuss the TMB analysis methods, the rationale to use TMB as a predictive biomarker and the clinical utility of TMB in NSCLC patients treated with ICIs." @default.
• W2897543997 created "2018-10-26" @default.
• W2897543997 creator A5001400077 @default.
• W2897543997 creator A5023794502 @default.
• W2897543997 creator A5090177578 @default.
• W2897543997 date "2018-12-01" @default.
• W2897543997 modified "2023-10-05" @default.
• W2897543997 title "Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy" @default.
• W2897543997 cites W1522752776 @default.
• W2897543997 cites W1607316259 @default.
• W2897543997 cites W1981876938 @default.
• W2897543997 cites W1994993231 @default.
• W2897543997 cites W2004630197 @default.
• W2897543997 cites W2009720434 @default.
• W2897543997 cites W2011458181 @default.
• W2897543997 cites W2016455125 @default.
• W2897543997 cites W2022414823 @default.
• W2897543997 cites W2039123767 @default.
• W2897543997 cites W2044433401 @default.
• W2897543997 cites W2049553585 @default.
• W2897543997 cites W2059300459 @default.
• W2897543997 cites W2069738344 @default.
• W2897543997 cites W2104347254 @default.
• W2897543997 cites W2124295966 @default.
• W2897543997 cites W2133775154 @default.
• W2897543997 cites W2152061559 @default.
• W2897543997 cites W2156353875 @default.
• W2897543997 cites W2160595349 @default.
• W2897543997 cites W2160981405 @default.
• W2897543997 cites W2198093519 @default.
• W2897543997 cites W2260067559 @default.
• W2897543997 cites W2291298003 @default.
• W2897543997 cites W2293531514 @default.
• W2897543997 cites W2339890238 @default.
• W2897543997 cites W2405335500 @default.
• W2897543997 cites W2467417577 @default.
• W2897543997 cites W2526607882 @default.
• W2897543997 cites W2527905628 @default.
• W2897543997 cites W2547187744 @default.
• W2897543997 cites W2560367415 @default.
• W2897543997 cites W2567564314 @default.
• W2897543997 cites W2572174216 @default.
• W2897543997 cites W2578528809 @default.
• W2897543997 cites W2595413783 @default.
• W2897543997 cites W2606495925 @default.
• W2897543997 cites W2613155082 @default.
• W2897543997 cites W2613362156 @default.
• W2897543997 cites W2622499649 @default.
• W2897543997 cites W2635951006 @default.
• W2897543997 cites W2756181170 @default.
• W2897543997 cites W2765314233 @default.
• W2897543997 cites W2765696340 @default.
• W2897543997 cites W2767891987 @default.
• W2897543997 cites W2779221466 @default.
• W2897543997 cites W2782949806 @default.
• W2897543997 cites W2783897381 @default.
• W2897543997 cites W2784283849 @default.
• W2897543997 cites W2795186863 @default.
• W2897543997 cites W2795505616 @default.
• W2897543997 cites W2796582438 @default.
• W2897543997 cites W2796865811 @default.
• W2897543997 cites W2797675588 @default.
• W2897543997 cites W2797855256 @default.
• W2897543997 cites W2888599070 @default.
• W2897543997 cites W2893501833 @default.
• W2897543997 cites W4229677521 @default.
• W2897543997 doi "https://doi.org/10.21037/tlcr.2018.09.22" @default.
• W2897543997 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6249615" @default.
• W2897543997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30505709" @default.
• W2897543997 hasPublicationYear "2018" @default.
• W2897543997 type Work @default.
• W2897543997 sameAs 2897543997 @default.
• W2897543997 citedByCount "63" @default.
• W2897543997 countsByYear W28975439972019 @default.
• W2897543997 countsByYear W28975439972020 @default.
• W2897543997 countsByYear W28975439972021 @default.
• W2897543997 countsByYear W28975439972022 @default.
• W2897543997 countsByYear W28975439972023 @default.
• W2897543997 crossrefType "journal-article" @default.
• W2897543997 hasAuthorship W2897543997A5001400077 @default.
• W2897543997 hasAuthorship W2897543997A5023794502 @default.
• W2897543997 hasAuthorship W2897543997A5090177578 @default.
• W2897543997 hasBestOaLocation W28975439971 @default.
• W2897543997 hasConcept C121608353 @default.
• W2897543997 hasConcept C126322002 @default.
• W2897543997 hasConcept C143998085 @default.
• W2897543997 hasConcept C203014093 @default.
• W2897543997 hasConcept C2775949291 @default.
• W2897543997 hasConcept C2776256026 @default.
• W2897543997 hasConcept C2777658100 @default.
• W2897543997 hasConcept C2777701055 @default.
• W2897543997 hasConcept C2780030458 @default.
• W2897543997 hasConcept C2780057760 @default.
• W2897543997 hasConcept C2908647359 @default.
• W2897543997 hasConcept C502942594 @default.
• W2897543997 hasConcept C71924100 @default.
• W2897543997 hasConcept C99454951 @default.
• W2897543997 hasConceptScore W2897543997C121608353 @default.

• next